tAnGo: a randomised phase III trial of gemcitabine in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy for early breast cancer: a prospective pulmonary, cardiac and hepatic function evaluation

tAnGo is a large randomised trial assessing the addition of gemcitabine(G) to paclitaxel(T), following epirubicin(E) and cyclophosphamide(C) in women with invasive higher risk early breast cancer. To assess the safety and tolerability of adding G, a detailed safety substudy was undertaken. A total o...

Descripción completa

Detalles Bibliográficos
Autores principales: Wardley, A M, Hiller, L, Howard, H C, Dunn, J A, Bowman, A, Coleman, R E, Fernando, I N, Ritchie, D M, Earl, H M, Poole, C J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2008
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2527826/
https://www.ncbi.nlm.nih.gov/pubmed/18665163
http://dx.doi.org/10.1038/sj.bjc.6604538

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2527826/
https://www.ncbi.nlm.nih.gov/pubmed/18665163
http://dx.doi.org/10.1038/sj.bjc.6604538

Ejemplares similares